184 related articles for article (PubMed ID: 11762336)
21. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer.
Makretsov N; Gilks CB; Coldman AJ; Hayes M; Huntsman D
Hum Pathol; 2003 Oct; 34(10):1001-8. PubMed ID: 14608533
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry of a component protein of the breast cystic disease fluid with mol. wt 15,000.
Le Doussal V; Zangerle PF; Collette J; Spyratos F; Hacene K; Briere M; Franchimont P; Gest J
Eur J Cancer Clin Oncol; 1985 Jun; 21(6):715-25. PubMed ID: 3894034
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical analysis of GCDFP-15 and GCDFP-24 in mammary and non-mammary tissue.
Satoh F; Umemura S; Osamura RY
Breast Cancer; 2000 Jan; 7(1):49-55. PubMed ID: 11029771
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein.
Ormsby AH; Snow JL; Su WP; Goellner JR
J Am Acad Dermatol; 1995 May; 32(5 Pt 1):711-6. PubMed ID: 7722013
[TBL] [Abstract][Full Text] [Related]
25. Apocrine ductal carcinoma in-situ with an unusual morphological presentation.
Coyne JD
Histopathology; 2001 Mar; 38(3):280. PubMed ID: 11260313
[No Abstract] [Full Text] [Related]
26. Biochemical correlates of morphologic differentiation in human breast cancer.
Silva JS; Cox CE; Wells SA; Paull D; Dilley WG; McCarty KS; Fetter BF; Glaubitz LC; McCarty KS
Surgery; 1982 Sep; 92(3):443-9. PubMed ID: 7202259
[TBL] [Abstract][Full Text] [Related]
27. Relation between apocrine differentiation and receptor status, prognosis and hormonal response in breast cancer.
Bundred NJ; Stewart HJ; Shaw DA; Forrest AP; Miller WR
Eur J Cancer; 1990; 26(11-12):1145-7. PubMed ID: 2149996
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical localization of gross cystic disease fluid protein-15, -24 and -44 in ductal carcinoma in situ of the breast: relationship to the degree of differentiation.
Selim AA; El-Ayat G; Wells CA
Histopathology; 2001 Aug; 39(2):198-202. PubMed ID: 11493337
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.
Lai BS; Tsang JY; Poon IK; Shao Y; Chan SK; Tam FK; Cheung SY; Shea KH; Tse GM
Oncologist; 2020 Sep; 25(9):e1318-e1329. PubMed ID: 32472950
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.
Lagendijk JH; Mullink H; van Diest PJ; Meijer GA; Meijer CJ
J Clin Pathol; 1999 Apr; 52(4):283-90. PubMed ID: 10474521
[TBL] [Abstract][Full Text] [Related]
31. Metastatic adenocarcinoma to the brain: an immunohistochemical approach.
Perry A; Parisi JE; Kurtin PJ
Hum Pathol; 1997 Aug; 28(8):938-43. PubMed ID: 9269830
[TBL] [Abstract][Full Text] [Related]
32. [Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas].
Bohrer MH; Schmoll J
Verh Dtsch Ges Pathol; 1993; 77():107-10. PubMed ID: 7511265
[TBL] [Abstract][Full Text] [Related]
33. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
Liu X; Feng C; Liu J; Zhao L; Liu J; Zhang W; Liu N; Niu Y
Tumour Biol; 2016 Jun; 37(6):8027-36. PubMed ID: 26711786
[TBL] [Abstract][Full Text] [Related]
34. [Spindle cell carcinoma of breast with neuroendocrine differentiation].
Ding HY; Gao LX
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):13-7. PubMed ID: 16608642
[TBL] [Abstract][Full Text] [Related]
35. Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs.
Cloutier J; Thompson ED; Cimino-Mathews A; Rooper LM; Matoso A; Argani P
Hum Pathol; 2018 Dec; 82():76-86. PubMed ID: 30031098
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
37. An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation.
Ansai S; Koseki S; Hozumi Y; Kondo S
Am J Dermatopathol; 1995 Jun; 17(3):249-55. PubMed ID: 8599433
[TBL] [Abstract][Full Text] [Related]
38. Breast gross cystic disease protein 15 in human breast cancer in culture.
Miller WR; Shivas AA; Franchimont P; Haagensen DE
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):223-8. PubMed ID: 3356211
[TBL] [Abstract][Full Text] [Related]
39. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin.
Wick MR; Lillemoe TJ; Copland GT; Swanson PE; Manivel JC; Kiang DT
Hum Pathol; 1989 Mar; 20(3):281-7. PubMed ID: 2542151
[TBL] [Abstract][Full Text] [Related]
40. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling.
López-Bonet E; Alonso-Ruano M; Barraza G; Vazquez-Martin A; Bernadó L; Menendez JA
Oncol Rep; 2008 Dec; 20(6):1369-74. PubMed ID: 19020716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
